Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 744 of 6351
-
New combo therapy aims to improve AML treatment for patients with specific gene changes
Disease control Recruiting nowThis phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or ML…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy takes on progressive MS
Disease control OngoingThe goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be g…
Phase 1 • Sponsor: Bruce Cree • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
Disease control Recruiting nowSOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also esta…
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Weekly shot aims to tame rare muscle diseases
Disease control Recruiting nowThe purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathi…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New gel could zap kidney cancer without surgery
Disease control Recruiting nowThe goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants who have a low-grade tumor. The main questions thi…
Phase 2/3 • Sponsor: Peter Black • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for rare muscle disease: experimental drug enters human trials
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SRP-1001 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive one dose of SRP-1001 or placebo.…
Phase 1/2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a replacement enzyme keep calcium buildup in check?
Disease control OngoingThe purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their con…
Phase 2 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Glow-in-the-Dark drug could help brain cancer surgery
Disease control CompletedThis trial is an open-label, multicenter, phase III clinical study,conducted in patients with newly diagnosed or recurrent malignant high-grade (WHO grades 3\~4) glioma, to evaluate the efficacy and safety of a single oral dose of 5-aminolevulinic acid (5-ALA) oral solution powde…
Phase 3 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to shrink inoperable esophageal tumors
Disease control Recruiting nowThis trial is conducted in patients with unresectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 60 patients with unresectable locally advanced esophageal cancer in Tianjin cancer hospital. After 2 cycles of induction immunochemotherapy…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for advanced breast cancer: drug combo trial shows promise
Disease control OngoingThis study is a phase II clinical trial to evaluate the safety and efficacy of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as first-line treatment in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for rare hormone disorder: drug targets Out-of-Control cortisol
Disease control Recruiting nowThis trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cort…
Phase 2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New program aims to cut hip fractures in nursing homes
Prevention OngoingHip fractures occur nearly twice as often for older adults residing in long-term care as they do in older adults of a similar age still living in other settings. Hip fractures are the leading cause of hospitalization and often result in loss of independence, problems with walking…
Sponsor: McMaster University • Aim: Prevention
Last updated Jul 15, 2026 00:00 UTC
-
A protein supplement may fight fatty liver in teens
Disease control CompletedParticipants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in…
Phase 3 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Gene-edited stem cells: a step toward transfusion-free life for β-thalassemia?
Disease control Recruiting nowThis is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)
Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
Heart attack patients may get safer blood thinners thanks to genetic test
Disease control Recruiting nowPatients who suffered from acute coronary syndrome (ACS) are usually treated with a long-term dual antiplatelet therapy (DAPT) to reduce stent thrombosis and recurrent ischemic event. Nonetheless, recent important data have demonstrated the efficacy of a short term DAPT and an ea…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can closing a heart hole stop strokes in seniors? new trial aims to find out
Disease control Recruiting nowPatent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years. Data in older patients is limited and since the population …
Sponsor: Josep Rodes-Cabau • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a Stress-Boosting drug make immunotherapy work for Hard-to-Treat colorectal cancer?
Disease control Recruiting nowThis Phase Ib trial studies the side effects and best dose of LB-100 when given with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune syst…
Phase 1 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a chatbot help teens avoid eating disorders?
Prevention Recruiting nowThe purpose of this study is to test an eating disorders prevention digital chatbot program in a diverse group of adolescents.
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated Jul 17, 2026 00:00 UTC
-
Can one targeted drug still work after another fails? new trial aims to find out
Disease control Recruiting nowThe purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+…
Phase 2 • Sponsor: Reshma L. Mahtani, D.O. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Eye implant could replace monthly shots for blinding disease
Disease control OngoingThis study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese pa…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC